Aisa Pharma has reported Phase 2 results from the RECONNOITER trial evaluating AISA-021, a reformulated version of cilnidipine, in patients with systemic sclerosis-associated Raynaud’s phenomenon, showing improvements in attack-free days and attack duration but failing to reach statistical significance on the study’s primary endpoint of weekly attack frequency. The U.S.-based biotech firm presented the data at the World Systemic Sclerosis Congress in Athens and indicated it plans to discuss Phase 3 study design and regulatory pathways with the United States Food and Drug Administration.

For clinicians and drug developers tracking systemic sclerosis complications, the RECONNOITER results illustrate both the persistent therapeutic gap in Raynaud’s management and the difficulty of demonstrating clear clinical benefit in small autoimmune disease trials. The results do not represent a regulatory breakthrough yet, but they do raise important questions about how Raynaud’s trials are designed, what endpoints regulators may accept, and whether older drug classes could be re-engineered to address complex vascular complications in autoimmune disease.

Why systemic sclerosis-associated Raynaud’s phenomenon remains one of the most difficult vascular complications to treat

Systemic sclerosis-associated Raynaud’s phenomenon occupies a unique place in rheumatology. The condition is widespread among patients with systemic sclerosis, affecting the vast majority of individuals with the disease and frequently representing one of its earliest and most debilitating manifestations. Episodes of vasospasm restrict blood flow to extremities, leading to pain, tissue ischemia, and in severe cases digital ulcers or permanent tissue damage.

Despite the severity of symptoms, there are currently no globally approved oral therapies specifically indicated for systemic sclerosis-associated Raynaud’s phenomenon. Treatment typically relies on off-label use of vasodilators such as calcium channel blockers, phosphodiesterase inhibitors, or endothelin receptor antagonists. The absence of approved therapies highlights the broader challenge of translating vascular biology insights into treatments that meaningfully improve patient outcomes.

What the RECONNOITER Phase 2 trial reveals about AISA-021 and the evolving clinical endpoints in Raynaud’s research

Against this backdrop, the AISA-021 program represents an attempt to revisit an established pharmacologic mechanism through a more targeted formulation strategy. Cilnidipine has been used for decades in Japan as an antihypertensive agent. The compound acts as a dual calcium channel blocker that targets both L-type and N-type channels, a combination that influences vascular smooth muscle tone while also modulating sympathetic nervous system signaling.

Aisa Pharma has attempted to adapt this pharmacology to Raynaud’s disease by developing a formulation designed to optimize vasodilation while limiting the neurological side effects associated with traditional calcium channel blockers. The theoretical rationale is straightforward. By targeting both vascular smooth muscle contraction and sympathetic nerve activity, the therapy could potentially address the underlying vasospastic processes that characterize Raynaud’s attacks.

The RECONNOITER trial tested this concept through a randomized, double-blind, placebo-controlled design involving 64 patients with active systemic sclerosis-associated Raynaud’s phenomenon. The study included a dose-finding component and a crossover component, allowing investigators to assess both safety and efficacy across treatment regimens.

The primary endpoint measured the change from baseline in the mean weekly frequency of Raynaud’s attacks. On that metric, AISA-021 reduced attack frequency by 22.1 percent compared with baseline, while placebo produced a 12.4 percent reduction. The difference did not achieve statistical significance.

Why missing the primary endpoint does not necessarily invalidate the clinical potential of AISA-021

At first glance, failure to meet a primary endpoint often raises concerns about the viability of a drug development program. Yet in rare diseases with small trials and variable symptoms, secondary endpoints frequently provide additional context.

In RECONNOITER, several secondary outcomes showed statistically significant improvement. Patients receiving AISA-021 experienced a large increase in attack-free days and a reduction in attack duration, suggesting that the therapy may alter the pattern of Raynaud’s episodes even if the frequency reduction did not reach significance.

For patients, attack duration and symptom severity can be as clinically meaningful as the number of attacks themselves. Shorter episodes may reduce pain, limit ischemic damage, and improve quality of life. Some rheumatology specialists believe that patient-reported outcomes such as attack-free days or symptom scores may ultimately become more relevant endpoints for evaluating therapies in this field.

How attack-free days and symptom duration could reshape endpoint selection in future Raynaud’s clinical trials

Industry observers note that this shift reflects a broader trend in rare disease trials. Traditional endpoints often emphasize quantitative measures that may not capture the full patient experience. As regulatory agencies increasingly consider patient-reported outcomes and functional metrics, trial designs may evolve accordingly.

The RECONNOITER findings therefore raise an important methodological question. If the therapy consistently improves measures such as attack-free days and attack duration, regulators may consider whether those endpoints should carry greater weight in future studies.

How real-world combination therapy complicates interpretation of efficacy signals in systemic sclerosis trials

Another noteworthy aspect of the trial involves the treatment context. Many participants were already receiving standard therapies for Raynaud’s symptoms when AISA-021 was added to their regimen.

This combination approach mirrors real-world practice, where patients frequently receive multiple vasodilators simultaneously. Demonstrating incremental benefit on top of existing therapies can therefore be clinically meaningful even if absolute efficacy appears modest.

However, combination therapy also complicates interpretation of clinical data. Improvements may reflect additive effects or interactions between drugs rather than the intrinsic efficacy of the investigational therapy. Larger Phase 3 trials will need to account for this variability.

What regulators will likely examine when Aisa Pharma discusses the Phase 3 pathway with the United States Food and Drug Administration

The safety profile reported in the study appears encouraging. AISA-021 was generally well tolerated and no treatment-related serious adverse events were reported during the trial.

Safety remains a crucial factor in systemic sclerosis treatment, as patients often require long-term therapy and may already be managing multiple comorbid conditions. A drug that improves symptoms but introduces significant cardiovascular or neurological risks would likely face adoption barriers.

Even if the safety profile remains favorable, several obstacles remain before AISA-021 could become a commercial therapy.

One challenge involves regulatory pathway clarity. Aisa Pharma has indicated it intends to meet with regulators to determine the design of a Phase 3 trial and potential registration strategy.

Such discussions will likely focus on endpoint selection, statistical power, and trial size. Because systemic sclerosis is a rare disease, regulators sometimes allow smaller pivotal trials, but they also expect robust evidence of clinical benefit.

What adoption barriers could limit uptake of AISA-021 even if Phase 3 results are positive

Another consideration involves market positioning. Even without approved therapies, Raynaud’s symptoms are already treated with widely available generic drugs. Any new therapy must therefore demonstrate clear advantages in efficacy, tolerability, or convenience.

AISA-021’s once-daily dosing may represent one differentiating feature. Many current vasodilator regimens require multiple daily doses or produce side effects that limit adherence.

Still, reimbursement dynamics could influence uptake. Payers may question the value of a branded therapy based on an older molecule unless clinical outcomes clearly surpass existing treatment options.

Manufacturing and formulation scalability also deserve attention. Reformulated versions of established drugs sometimes face complex intellectual property and supply chain considerations. Aisa Pharma has indicated it developed a proprietary manufacturing process for the compound, but large-scale production would need to support global distribution if the therapy reaches approval.

What clinicians, regulators, and rare disease investors will watch as the AISA-021 program advances toward pivotal studies

Beyond the immediate Raynaud’s indication, the company has suggested the drug’s mechanism could extend to additional conditions, including pulmonary fibrosis and neuropathic pain.

Such expansion strategies are common in rare disease drug development. By targeting related vascular or inflammatory pathways, companies attempt to broaden the commercial potential of a single platform therapy.

However, these broader ambitions will likely depend on the success of the Raynaud’s program. Demonstrating efficacy in systemic sclerosis-associated vascular disease could provide proof of concept for other indications.

For clinicians, the most immediate question is whether the Phase 2 findings justify optimism. The therapy appears biologically active, producing measurable improvements in several clinically relevant endpoints, yet the missed primary endpoint highlights the difficulty of translating physiological effects into statistically robust outcomes.

Regulators and clinical investigators will likely watch several developments closely as the program moves forward, including endpoint selection for the Phase 3 trial, patient selection and baseline therapy management, and statistical assumptions for pivotal studies.

For now, the RECONNOITER trial serves less as a definitive breakthrough and more as a signal that the search for effective therapies in systemic sclerosis-associated Raynaud’s phenomenon remains active. The data suggest progress may be possible, but the path to regulatory approval and clinical adoption remains uncertain.

  Aisa Pharma, AISA-021, autoimmune disease, cilnidipine, orphan drug designation, rare disease therapeutics, Raynaud’s phenomenon, RECONNOITER trial, systemic sclerosis, vascular disorders